AL-102 is a small molecule commercialized by Ayala Pharmaceuticals, with a leading Phase III program in Benign Tumor. According to Globaldata, it is involved in 4 clinical trials, of which 2 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of AL-102’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for AL-102 is expected to reach an annual total of $88 mn by 2032 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

AL-102 Overview

BMS-986115 (AL-102) is under development for the treatment of desmoid tumors, relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and relapsed/refractory multiple myeloma. It is administered orally. The drug candidate is a pan-notch gamma secretase inhibitor.

It was under development for the treatment of advanced solid tumors

Ayala Pharmaceuticals Overview

Ayala Pharmaceuticals Inc (Ayala Pharmaceuticals) is a clinical-stage bio-pharmaceutical company which develops novel drugs for defined cancers. Its lead product candidate AL101 and AL102 to treat cancers. The products render different cancers like desmoid tumors, adenoid cystic carcinoma (ACC), triple negative breast cancer (TNBC) and T-cell acute lymphoblastic leukemia (T-ALL). Ayala Pharmaceuticals desmoid tumors arise in upper and lower extremities, abdominal wall, head and neck area, mesenteric root and chest wall of the body. In addition, it also focuses on inhibiting the Notch activating pathway with best-in-class gamma secretase inhibitors (GSIs). The company has operations in Israel and the US. Ayala Pharmaceuticals is headquartered in Wilmington, Delaware, the US.

For a complete picture of AL-102’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.